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ABSTRACT 
Polyethylene glycol (PEG) coating has been frequently used to improve the 
pharmacokinetic behavior of nanoparticles. Studies which contribute to better unravel 
the effects of PEGylation on the toxicity of nanoparticle formulation are therefore 
highly relevant. In the present study, reduced graphene oxide (rGO) was functionalized 
with PEG and its effects on key components of the blood-brain barrier, such as 
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astrocytes and endothelial cells, were analyzed in culture and in an in vivo rat model.  
The in vitro studies demonstrated concentration-dependent toxicity. The highest 
concentration (100 µg/ml) of non-PEGylated rGO had a lower toxic influence on cell 
viability in primary cultures of astrocytes and rat brain endothelial cells (RBECs), while 
PEGylated rGO induced deleterious effects and cell death. We assessed hippocampal 
BBB integrity in vivo by evaluating astrocyte activation and the expression of the 
endothelial tight and adherens junctions proteins. From 1 h to 7 days post-rGO-PEG 
systemic injection, a notable and progressive down-regulation of protein markers of 
astrocytes (GFAP, connexin-43), the endothelial tight (occludin) and adherens (β-
catenin) junctions, and basal lamina (laminin) were observed. The formation of 
intracellular ROS demonstrated by increases in the enzymatic antioxidant system in the 
PEGylated rGO samples was indicative of oxidative stress-mediated damage. Under the 
experimental conditions and design of the present study the PEGylation of rGO did not 
improve interaction with components of the blood-brain barrier. In contrast, the 
attachment of PEG to rGO induced deleterious effects in comparison with the effects 
caused by non-PEGylated rGO. 
 
KEYWORDS: PEGylation, graphene-based nanomaterials, central nervous system, 
Nanotoxicity 
 
1. INTRODUCTION 
Since its discovery in 2004, graphene and derivatives, such as graphene 
oxide (GO) and reduced graphene oxide (rGO), have been extensively studied in many 
different fields. Their remarkable electronic, optical, magnetic, thermal and mechanical 
properties lead to the broad-spectrum application of these nanomaterials in 
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neuroscience, biomedicine, bioimaging, biosensor development, drug/gene delivery, 
photothermal therapy and tissue engineering [1-4]. 
Typically, the nanomaterial surface can be tailored through chemical 
modification to enhance such properties. One of the most common of these 
modifications is PEGylation, which is the process of the covalent and non-covalent 
attachment of polyethylene glycol (PEG) molecules to the surface of nanomaterials. 
PEG is a polymer composed of repetitive subunits of ethylene ether, available in 
different molecular masses, variable branched chain lengths and terminal functional 
groups. The attachment of PEG improves the stability and solubility of nanomaterials in 
physiological solutions and reduces their accumulation in the reticuloendothelial 
system, thus prolonging blood circulation half-life and improving pharmacokinetic 
behavior [5, 6]. Conversely, some studies have identified minimal benefits and even 
described detrimental effects on the improving nanoparticle circulation half-life [7], 
nanoparticle uptake and reductions in overall toxicity [8, 9]. This may be due to a 
variety of physicochemical properties (e.g., size, surface charge, chemical composition 
and aggregation) that can be altered by PEGylation and significantly affecting the 
physiological interactions between nanomaterials and biological targets. 
The interplay between PEGylated graphene-based nanomaterials and the central 
nervous system (CNS) are poorly understood, and details about their toxicological 
characteristics to support the rational design and development of new nanomaterials are 
lacking. 
We have previously demonstrated that water-suspended rGO injected in rats 
through the tail vein (i.v.) induces a transient disruption of the paracellular tightness of 
the blood-brain barrier (BBB) in the hippocampus [10], with a relatively low 
toxicity for the vital organs [11]. The BBB is a dynamic interface that separates the 
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peripheral circulating blood and the CNS microenvironment. The BBB plays a major 
role in the maintenance of the homeostasis of the brain by regulating ion traffic, entry of 
xenobiotics or potentially harmful molecules, and at the same time mediates the 
transport of nutrients to the brain parenchyma. Formed by specialized non-fenestrated 
vascular endothelial cells, the BBB is tightly controlled by astrocytes, pericytes 
embedded in the vascular basement membrane, microglia and neurons. The 
neurovascular unit consists of endothelium, astrocytes, pericytes and neurons, 
highlighting the close interconnection between the BBB and neural functionality [12, 
13].   
In the present study, we functionalized rGO with PEG and investigated its in 
vitro and in vivo effects on the BBB. By investigating the response of astrocytes and rat 
brain endothelial cells (RBECs) to non-PEGylated and PEGylated rGO we hope to 
provide a better understanding of the interactions between these graphene derivatives in 
living cells and organisms. The study will also contribute to an improved 
characterization of the effects of PEGylation on graphene-based nanomaterials. 
 
2. EXPERIMENTAL SECTION  
 
2.1 Chemicals. All chemicals used in rGO-PEG synthesis and cell culture were 
obtained from Sigma-Aldrich, unless stated otherwise.   
 
2.2 rGO-PEG Synthesis and Characterization. The detailed synthesis of rGO was 
described previously [10]. Here, we aimed to functionalize rGO with PEG by simple 
mixing both in order to initiate physical adsorption. Briefly, an aqueous solution of PEG 
6,000 (1 mg/ml) was prepared. The mixture was bath-sonicated for 15 min and the 
Page 4 of 39
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5 
 
aqueous suspension of rGO (1 mg/ml) was added to the solution (1:1). After incubation 
under ultrasonication for 30 min at room temperature, the solution contained the rGO-
PEG final product.  
 The PEGylation was further confirmed by Fourier-transform infrared 
spectroscopy in attenuated total reflectance mode (FTIR-ATR) using a FTIR 
Spectrophotometer (Shimadzu-8400S, Kyoto, Japan). Forty scans were taken with the 
resolution of 4 cm-1 in the region of 4000-400 cm-1. The nuclear magnetic resonance 
(NMR) spectra of 13C were recorded at room temperature under magic angle spinning 
with a Bruker Avance 300 spectrometer operating at 75 MHz. Thermogravimetric 
analyses (TGA) and differential scanning calorimetry (DSC) curves were recorded on 
Shimadzu TGA-50 and Shimadzu DSC-60 instruments, respectively, under 
nitrogen purge with a heating rate of 10 °C/min.  
 Dynamic light scattering (DLS) technique was used for the measurement of 
size, polydispersity index (PDI) and zeta potential of the rGO-PEG suspension using a 
ZetaSizer Nano ZS 90 instrument (Malvern Instruments Ltd., Worcestershire, UK). The 
results were expressed as the average of three measurements.  
 Morphological analysis of the sample was done with field emission scanning 
electron microscope (FE-SEM) (Zeiss Supra 55 VP-SEM) and high-resolution 
transmission electron microscopy (HRTEM) using a JEOL JSM-6330F microscope 
operated at 300 kV as previously described [10].  
 
2.3 Cell culture. Isolation of astrocytes and RBECs was carried out following the 
national and international recommendations for the care and use of laboratory animals. 
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2.3.1 Astrocytes. Astrocytes were prepared from newborn Wistar rats (Rattus 
norvegicus) by mechanical dissociation of the brain tissue and filtering through a cell 
strainer of 40 µm pore size. Cells were cultured until confluence on poly-L-lysine-
coated dishes and frozen in Bambanker cell freezing medium (Nippon Genetics). Before 
use, cells were plated into poly-L-lysine-coated 96-well plates or 8-well microscopy 
culture chambers (for immunofluorescence assays) and cultured until confluence. Cells 
were used at passage number P1. 
 
2.3.2 RBECs. RBECs were prepared from three-week-old Wistar rats. Under sterile 
conditions, brains were gently dissected, and forebrains collected in ice-cold phosphate 
buffered saline (PBS). The meninges were carefully removed using sterile 
chromatography paper, cut into small pieces and digested in two enzymatic steps: (1) 
collagenase type 2 and DNAse I in DMEM/F12 (Life Technologies, Budapest, 
Hungary) at 37°C for 75 minutes, and (2) collagenase/dispase and DNAse I in 
DMEM/F12 at 37°C for 50 minutes. Myelin was removed by centrifugation on 20% 
bovine serum albumin (BSA) between the two digestion steps. The digested 
microvessel fragments were separated on a continuous 33% Percoll gradient and plated 
onto fibronectin/collagen type IV-coated dishes; 96-well plates, E-plates (ACEA 
Biosciences, San Diego, USA) or Transwell (#3470; Corning Life Sciences, Corning, 
USA) permeable polyester filters (0.4 µm pore size, 0.33-cm2 surface area). Cells were 
maintained in DMEM/F12 containing 10% plasma-derived serum (PDS, First Link, 
Wolverhampton, UK), 1 ng/ml basic fibroblast growth factor (Sigma Aldrich), 100 
µg/ml heparin, and 5 µg/ml insulin-transferrin-selenite at 37°C and 5% CO2. In the first 
two days, 4 µg/ml puromycin was added to remove contaminating cells. Three days 
after isolation, RBECs reached confluence and were treated with 550 nM 
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hydrocortisone, 250 µM CTP-cAMP and 17.5 µM 4-(3-butoxy-4-
methoxybenzyl)imidazolidin-2-one (RO-201724) to induce BBB characteristics [14]. 
 
2.4 Toxicity measurements. The in vitro concentration of rGO-PEG (100 µg/ml) was 
selected as a function of the concentration already used for in vivo experiments 
(7 mg/kg) [10, 11]. For the calculation, we considered a 200 g rat with blood volume 
average of 14 ml [15]. We also used a concentration 10 times lower than the threshold 
concentration, able to induce oxidative stress and DNA damage in some cell lines [16]. 
 
2.4.1 EZ4U assay. Cell viability was detected using EZ4U assay (Biomedica 
Medizinprodukte, Vienna, Austria). Cells were seeded in 96-well coated plate (Corning 
Technologies, Corning, NY, USA) and after reaching confluence the cells were treated 
with culture medium (negative control), rGO-PEG or vehicle (PEG 6,000) for 3 h 30 
min (RBECs) or 24 h (Astrocytes). For the sake of comparison, we also treated the cells 
with an aqueous suspension of rGO and its vehicle (sterile distilled water) using the 
same concentrations as for other treatments. After washing the cells with phenol-red 
free DMEM, the EZ4U assay was performed according to the manufacturer’s 
instructions. The method is based on the reduction of tetrazolium salt to colored 
formazan by the mitochondria of living cells.The absorbance was recorded using a 
microplate reader (FLUOstar Optima; BMG Labtechnologies, Offenburg, Germany) at 
492 nm and values were compared to control cells. To confirm that rGO-PEG was not 
able to spontaneously metabolize the EZ4U substrate, we also measured the response of 
rGO-PEG in the absence of cells. rGO-PEG alone was not able to reduce uncolored 
tetrazolium salts into intensely colored formazan derivate. 
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2.4.2 Cell impedance measurements. Cell impedance was detected using the 
xCELLigence system (ACEA, San Diego, CA, USA). It is a cell-based label-free 
method that measures in real time electrical impedance across gold electrodes placed at 
the bottom of a 96-well plate (E-plate 96, ACEA Biosciences). Further, the 
xCELLigence software (version 1.2.1) converts the electrical impedance to a cell index 
(CI) value (arbitrary units). In general, under the same physiologic conditions, if more 
cells are attached to the electrodes, the impedance value is higher, leading to increased 
CI. Contrarily, in the absence of cells, i.e., cell death or toxicity-induced cell 
detachment; a lower CI value is obtained. The impedance depends on the tightness of 
the junctions as well. 
 Cells were seeded in E-plates and the impedance was continuously monitored 
until cells reached a steady phase (confluence and well-formed tight junctions in the 
case of RBECs), when they were treated with rGO or rGO-PEG. Impedance was 
monitored every 1 h during 24 h. 
 
2.5 Immunofluorescence (IF). Cells were fixed in 95% ethanol/5% acetic acid at -
20°C for 5 minutes. After blocking with 3% BSA- for 30 min, samples were incubated 
overnight with primary antibodies (Table 1). The staining was visualized using Alexa 
594- (GFAP), Alexa 488- (Aquaporin-4, Occludin) or Cy5-conjugated (Claudin-5) 
secondary antibodies. Nuclear staining of the cells was carried out using Hoechst 
33342. Images were recorded by a Nikon Eclipse TE2000U photomicroscope with 
epifluorescent capabilities connected to a digital camera (Spot RT KE). 
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Table 1. Primary antibodies used in this study. 
Antibody Dilution Source Catalog number Technique 
Aquaporin-4 
β-catenin 
1:100 
1:500 
Santa Cruz 
Santa Cruz 
Sc-20812 
sc-7963 
IF 
WB 
Catalase (CAT) 1:400 Santa Cruz sc-271242 WB 
Claudin-5 1:100 Invitrogen 35-2500 IF 
Connexin-43 (Cx43) 1:500 Santa Cruz sc-9059 WB 
GFAP 
GFAP 
1:500 
1:500 
Dako 
Dako 
Z0334 
Z0334 
WB 
IHC 
GFAP 1:10000 Sigma Aldrich G3893 IF 
Laminin 1:500 Sigma Aldrich L9393 WB 
Occludin 1:500 Santa Cruz sc-5562 WB 
Occludin 1:100 Invitrogen 71-1500 IF 
Superoxide dismutase-1 (SOD-1) 1:500 Santa Cruz sc-11407 WB 
β-actin 1:1000 Sigma Aldrich A2228 WB 
IF: Immunofluorescence; IHC: Immunohistochemistry; WB: Western blotting. 
 
2.6 ROS measurements. Cells were treated in 96-well plates for 3h 30 min (RBECs) 
and 24 h (Astrocytes), washed with Ringer-HEPES and incubated for 1 h in Ringer-
HEPES containing 2 µM CM-H2DCFDA (Molecular Probes/Thermo Fisher 
Scientific) and 25 µg/ml Pluronic F-. CM-H2DCFDA passively diffuses into cells, 
where it is modified by intracellular esterases and thiols while subsequent oxidation 
results in a fluorescent product. Fluorescence was monitored using a FLUOstar 
Optima microplate reader equipped with a 492/520 nm excitation/emission filter set.  
 
2.7 Animal care and rGO-PEG systemic administration. All in vivo experiments 
were carried out at State University of Campinas and approved by the institutional 
Committee for Ethics in Animal Use (protocol no. 2884-1) and followed the Brazilian 
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Society of Laboratory Animal Science guidelines. Male Wistar rats (Rattus norvegicus, 
6-week-old, 180 ± 40 g) received a single i.v. injection of rGO-PEG (7 mg/kg; 
concentration 1 mg/ml) [10,11], while to the control group was given the same volume 
of vehicle (PEG 6,000). For the sake of comparison, we treated the cells with an 
aqueous suspension of rGO and its vehicle, using the same concentrations.  
All animals were euthanized by carbon dioxide (CO2) or anesthetics overdose 
(3:1 mixture of ketamine chloride (Dopalen®, 100 mg/kg body weight,) and xylazine 
chloride (Anasedan®, 10 mg/kg body weight, Fortvale, Valinhos, SP, Brazil) 15 min, 1 
h, 3 h and 7 days after the i.v. administration of rGO-PEG. Animals of the control group 
were euthanized 1 h later. A single control group was used as preliminary experiments 
showed no time difference relative to data.  
 
2.8 Western blotting (WB). WB was performed in hippocampal homogenates (n = 5 
for each time, including a single control group killed 1 h after vehicle injection). 
Briefly, after being blocked with 5% (v/v) skimmed milk in TBS-T (0.1 % Tris-buffered 
saline with 0.05 % Tween 20, pH 7.4) for 1 h at room temperature; the membranes were 
incubated at 4°C overnight with primary antibody (Table 1). After washing with TBS-T, 
the membranes were incubated for 2 h at room temperature with the respective HRP-
labeled secondary antibody (1:1000).  Immunoreactive bands were visualized using a 
chemiluminescence kit (Super Signal West Pico Chemiluminescent Substrate; Pierce 
Biotechnology, Rockford, IL, USA) and recorded with a G:BoxiChemi camera 
(Syngene, Cambridge, UK). The blots were subsequently stripped and probed with anti-
β-actin to monitor protein loading, the efficiency of blot transfer, and nonspecific 
changes in protein levels.  Bands intensities were quantified using ImageJ 1.45s 
software (NIH, Bethesda, MD, USA).  
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2.9 Immunohistochemistry (IHC). Paraffin-embedded brain sections of 5 µm-
thickness were dewaxed and rehydrated, washed in 0.05 M phosphate-buffered 
saline (PBS; pH 7.4) and subjected to heat-mediated antigen retrieval treatment using 10 
mM sodium citrate buffer for 30 min. Endogenous peroxidase activity was quenched 
with 3 % hydrogen peroxide for 20 min and then washed twice with PBS. Unspecific 
epitopes were blocked with 5 % skimmed milk powder for 1 h following overnight 
incubation with GFAP in a humidified chamber at 4 °C. After washing twice with PBS, 
the slides were incubated with the biotinylated anti-rabbit secondary antibody 
(EnVision_HRP link, Dako Cytomation, CA, USA) for 30 min at room temperature. 
Immunoreactivity was visualized as a brownish color after staining with a 
diaminobenzidine chromogenic solution (DAB+, Dako Cytomation) and nuclei were 
counterstained with Harry’s hematoxylin; after ethanol dehydration slides were 
mounted in Entellan (Merck, Darmstadt, Germany). Parallel negative control 
was performed by replacing the primary antibody with 1 % PBS-bovine serum albumin. 
Images were recorded by a Nikon Eclipse E800 photomicroscope connected to a digital 
camera (CoolSnap-Pro Color).  
 
2.10 Evaluation of oxidative stress parameters. The blood samples were collected via 
cardiac puncture in serum separator gel tube (n = 3-5 for each time, including a single 
control group killed 1 h after vehicle injection). The enzyme antioxidant systems (SOD 
and CAT) in the serum samples were measured using colorimetric methods. The SOD 
activity in serum was obtained after reaction with hypoxanthine, nitroblue tetrazolium 
and 0.07 U of xanthine oxidase as described in detail before [17]. The CAT activity 
method was carried out based on the reaction of the enzyme with methanol and H2O2. 
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Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) was used as chromogen and 
the resultant formaldehyde products were measured at 540 nm (adapted from [18]).  
Lipid peroxidation was determined by measuring TBARS using 
a spectrophotometric method described by Ohkawa et al. [19] and adapted by Batista et 
al. [17] in which malondialdehyde and the final products of lipid peroxidation react with 
thiobarbituric acid, forming a pink-colored complex. 
 
2.11 Statistical analysis. All data are expressed as mean ± SEM. Statistically 
significant differences were assessed by Student’s t test or One-way ANOVA followed 
by Tukey multiple comparison post-hoc test with a p-value < 0.05 considered 
significant. Graphs were prepared with Prism software, version 5 (GraphPad Inc., La 
Jolla, CA, USA) and all of the data are expressed as mean ± SEM.  
 
3. RESULTS AND DISCUSSION 
 
3.1 Preparation and characterization of PEGylated rGO 
 Table 2 summarizes the main physicochemical characteristics of the non-
PEGylated and PEGylated rGO measured by DLS. 
 
Table 2. Physicochemical characteristics of non-PEGylated and PEGylated rGO. 
Samples Size (nm) Zeta potential (mV) PDI 
Non-PEGylated rGO 342 ± 23.5 −25 ± 0.18 0.56 ± 0.03 
PEGylated rGO 910 ± 32.7 -4.2 ± 3.8 0.39 ± 0.04 
 
  A comparison of zeta potential revealed that the charge associated with the non-
PEG rGO had a greater negative zeta potential (−25 ± 0.18 mV) than the PEGylated 
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rGO (-4.2 ± 3.8 mV). This suggests the existence of positive amino-ended branches, 
resulting in a lesser negative electrostatic charge for PEGylated rGO than rGO (Vila et 
al. 2012). The PEGylation of rGO leads to a decrease in PDI values (0.56 ± 0.03 to 0.39 
± 0.04), resulting in the diminished polydispersity of particles, probably due to a lower 
susceptibility to aggregate formation.  
A significant increase in size, from 342 ± 23.5 nm up to 910 ± 32.7 nm, was 
found after PEGylation. Although this increase offers evidence for the PEGylation of 
nanoparticles, confirmation of the attachment of PEG to rGO is essential. For this 
purpose, FTIR-ATR, 13C NMR and TGA-DSC were carried out. As shown in Figure 
1A, the PEGylated rGO spectrum exhibited characteristic bands at 1080 cm-1 (-C-O-C 
stretching), 1641 cm-1 (C=O stretching) and 3359 cm-1 (O–H stretching), indicating 
cross-linking between PEG and rGO [20]. According to the TGA-DSC measurement 
results, the ratio of grafted PEG was estimated to be 78.85% (Fig. 1B). The 13C NMR 
spectrum of rGO exhibited a peak at 100 ppm (Fig. 1C) while rGO-PEG exhibited a 
peak at 70 ppm (Fig. 1D). All ethylene glycol carbons have approximately the same 
microenvironment, and are thus expected to have similar chemical shift values at around 
70 ppm corresponding to –O-CH2 group of PEG [21].  
The morphology and structure of rGO-PEG analyzed by FE-SEM and HRTEM also 
showed wrinkles, lateral corrugations and a scrolled appearance of rGO-PEG (Figure 
1C, D). The surface morphology and structural parameters of non-PEGylated rGO have 
been previously demonstrated [10, 11]. 
 
3.2 PEGylation of rGO increased its toxicity in astrocytes and RBECs 
We began by investigating the effects of rGO-PEG exposure on the viability of 
primary rat astrocytes and RBECs using EZ4U assay and the xCELLigence system. 
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This system measures electrical impedance across the cell monolayer using a high-
density electrode array that coats the bottom of the well, and converts the impedance 
values to a Cell Index. These cell index values directly correspond to the change in the 
viability status of the cell [22].  
The viability of astrocytes was assessed after exposure to culture medium for 24 
h (negative control), rGO-PEG or vehicle (PEG), at concentrations of 10 µg/ml and 100 
µg/ml. For the sake of comparison, we treated the cells with an aqueous suspension of 
rGO and its vehicle, using the same concentrations as the other treatments.  
As shown in Figure 2, both vehicles (sterile distilled water and PEG) had no 
toxic effect on astrocytes, whereas PEG (100 µg/ml) induced a significant increase in 
cell viability compared to all the other groups (p<0.001). No substantial differences 
were observed between controls and cells treated with non-PEGylated rGO. 
Surprisingly, the viability of astrocytes decreased from 126% to 16% (p<0.001) when 
the astrocytes were treated with 100 µg/ml of rGO-PEG (Figure 2A).  
Similar dose-dependent toxic effects of rGO, dispersed with PEG, Pluronic P123 
or sodium deoxycholate (DOC), were reported by Wojtoniszak et al. [23]. These studies 
were carried out using L929 mouse fibroblasts and rGO concentrations ranging from 
3.125 to 100 µg/ml.  The authors found that rGO-PEG exhibited the greatest 
biocompatibility with respect to Pluronic P123 and DOC. Cells exposed to the 
suspension of rGO-PEG at concentrations between 3.125 µg/mL and 25 µg/mL 
displayed relatively high viability; however, when the concentration exceeded 
25 µg/mL, viability was abruptly reduced. 
 In another work, Vila et al. [24] conducted a comparative study of how the 
number of branches of the PEG molecule affects the cellular uptake and cytotoxicity of 
GO. The cellular uptake of linear PEGylated GO (sized 95 nm) was significantly higher 
Page 14 of 39
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15 
 
than that of branched PEGylated GO (sized 190 nm) in osteoblasts, fibroblasts and 
macrophages. Moreover, branched PEG (75 µg/mL) induced more changes in cellular 
function than its linear counterpart. 
All experiments using xCELLigence were performed using only the highest 
concentration (100 µg/ml) of rGO and rGO-PEG, which was responsible for the 
reduction in astrocyte viability.  The xCELLigence system with real-time technology 
allows us to dynamically observe the decrease of the cell index curve.  
Very similar toxicity patterns were observed for the PEGylated rGO-treated cells 
using both techniques. Although alterations in the viability of astrocytes treated with 
non-PEGylated rGO were not found using EZ4U assay (Figure 2A), the cell index of 
rGO-treated cells was lower than the control vehicle (Figure 2B).  This may be the 
result of minor morphological changes in the cells affecting the cell index [25]. 
Immunostaining of the astrocytic markers GFAP and Aquaporin-4 was used to 
analyze morphological alterations in the astrocytes exposed for 24 h to non-PEGylated 
and PEGylated-rGO. Immunostaining resulted in clear immunoreactivity for both 
proteins, with an almost total overlap. When compared to the control cells (Figure 2C, 
F), both rGO and rGO-PEG produced morphological changes in the rat astrocytes. 
Astrocytes treated with rGO presented moderate body and process retraction (Figure 
2D, G), while astrocytes treated with rGO-PEG exhibited a complete absence of normal 
cell structure, the loss of cell-to-cell contact, and a noticeable reduction in the number of 
astrocytes (Figure 2E, H).  
 The cultured astrocytes presented atrophy and cell death after 24 h of exposure 
to PEGylated rGO. It is well known that CNS injury activates astrocytes in a process 
known as reactive gliosis or astrogliosis, which is manifested through astrocyte 
hyperplasia or hypertrophy of cell processes caused by variable up-regulation of 
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cytoskeletal-forming GFAP [26]. However, Zhao et al. [27] have reported that damage 
to or death of astrocytes can occur in the early periods after brain injury, with 
concomitant down-regulation of GFAP immunoreactivity, which can be followed in 
later periods by reactive GFAP upregulation and the formation of glia scars to protect 
the injured region of the brain.  
As rGO-PEG displayed cytotoxic effects on astrocytes, we subsequently 
assessed the impact of rGO-PEG upon RBECs with BBB phenotype. After 24 h of 
incubation with supplements which enhanced the BBB phenotype, once the growth of 
the RBECs reached a steady plateau, we began treatment with nanomaterials. As the 
brain endothelial cells are more sensitive to injury than astrocytes, the viability of the 
RBECs was assessed after exposure to treatments for 3 h 30 min.  
As for the astrocytes, no substantial differences were observed in cells treated 
with non-PEGylated rGO. The 10 µg/ml and 100 µg/ml PEG groups had significantly 
higher levels than all the other groups (p<0.001). Cell viability also decreased in RBECs 
incubated with 100 µg/ml of rGO-PEG (p<0.001) (Figure 3A). 
Cell index values were monitored continuously for 24 h. While rGO induced a 
slight decrease in the cell index, rGO-PEG treatment led to a rapid reduction within 5 h. 
This drop was much more pronounced than that seen in astrocytes in response to similar 
treatment. This suggests that astrocytes are more resistant to toxic insult than 
endothelial cells. This finding is in line with earlier results showing that cerebral 
endothelial cells had a higher susceptibility to oxidative stress than astrocytes [28]. PEG 
alone did not affect the cell index during long-term treatment (Figure 3A), indicating 
that the polymer has no damaging effects on RBECs. In some cases, PEG by itself can 
even enhance the properties of the endothelial barrier [29].  
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Immunofluorescent studies using antibodies directed against junctional proteins 
shed light on the molecular background of decreased functionality of the cerebral 
endothelium in response to rGO-PEG treatment. Under control conditions, fine, 
continuous membrane staining was observed (Figure 3C, E).  However, the 
expression patterns of the TJ proteins were significantly altered in the rGO- and rGO-
PEG-treated groups. The rGO group showed irregular and discontinuous expression of 
occludin and claudin 5 (Figure 3D, inset), while rGO-PEG induced widespread 
disruption of the RBEC monolayer, which is indicative of cell-cell junction damage 
(Figure 3F). 
Occludin and claudins are transmembrane proteins of the tight junctions, and 
control paracellular permeability. In cerebral endothelial cells claudin-5 plays a more 
important role, with a lack of this protein leading to the opening of the BBB for 
substances with a molecular weight of less than 800 Da [30]. Our results indicate that 
rGO-PEG has a barrier damaging effect when used in high concentrations. 
 
3.3 rGO-PEG induced BBB breakdown and in vivo astrocyte dysfunction  
While in vitro models are practical and cost-effective methods for screening the 
toxicity of potential drug carriers, they cannot completely replace the complexity of 
animal and human responses. Therefore, the following step was carried out to 
investigate the in vivo effects of rGO-PEG.  
We had previously detected the presence of rGO inside the thalamus and 
hippocampus by matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry imaging (MSI). We also found that intravenous (i.v.) injection of rGO 
induced a transient blood-brain barrier opening in the hippocampus. We found 
downregulation of junctional proteins (the tight junction protein occluding and the 
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adherens junction protein β-catenin) and laminin. When taken together, these are co-
responsible for maintaining the paracellular tightness of the BBB [10]. In the present 
study, we used the same rat model and experimental design to evaluate the expression 
of these three BBB-associated proteins in the rat hippocampus after rGO-PEG i.v. 
administration. 
The rGO-PEG caused a significant decrease in occludin (32%, p<0.01), β-
catenin (85%, p<0.001) and laminin (134%, p<0.01) levels 3 h after administration. 
This did not increase thereafter; instead, by day 7, the proteins had reached their highest 
level of down-regulation (p<0.001) (Figure 4). 
 The significant and long-lasting downregulation of BBB-associated proteins 
induced by PEGylated rGO implies impaired BBB function and probably a homeostatic 
disturbance of the hippocampal milieu. In contrast, non-PEGylated rGO induced a 
transient and slighter down-regulation of BBB-associated proteins which was resolved 
seven days post-rGO exposure [10], an indication that rGO is more qualified than GO-
PEG in terms of being explored in the field of neuroscience research. 
Analysis of hippocampal homogenates from non-PEGylated rGO-treated rats did 
not show significant changes in the levels of GFAP (Figure 5A) and Cx43 (Figure 5B).  
Unexpectedly, the stimulus generated by rGO-PEG did not increase the expression of 
GFAP, either acutely or in late periods following administration. Instead, it induced a 
decrease in the expression of GFAP at 3 h (47%, p<0.05) and 7 days (95%, p<0.001) 
post-rGO-PEG injection (Figure 5A), in comparison with the control vehicle. An 
explanation for this data is given by the findings obtained for in vitro-cultured 
astrocytes, which unarguably demonstrated a significant decrease in astrocyte viability 
through EZ4U assay and xCELLigence. Immunohistochemical analysis of GFAP-
positive cells in the hippocampus (Fig. 5 C-E) corroborated the in vitro data. Therefore, 
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we can state that the decrease of GFAP expression in the hippocampus of rats i.v. 
injected with rGO-PEG, but not with non-PEGylated rGO, was due to the death of a 
number of astrocytes.   
Similarly to GFAP, the i.v. injection of rGO-PEG led to a reduction in Cx43 
expression at 3 h and 7 days (159%, p<0.001) (Figure 5B) when compared to the 
control vehicle. These findings offer a plausible hypothesis that the strong retraction of 
the astrocyte processes and a loss of viability (seen in in vitro preparations) most likely 
eliminated homotypic contacts among the astrocyte processes, and even heterotypic 
contacts among astrocytes and endothelial cells and/or neuronal cells, also in vivo. 
Therefore, we suggest that the long-lasting and progressive decrease of Cx43 from 3 h 
to 7 days following the systemic administration of rGO-PEG, but not after the 
administration of non-PEGylated rGO, impaired the exchange of information among 
astrocytes due to non-operant GJs.  
Astrocytes are key regulators of BBB integrity and have an impressive capacity 
to modulate CNS homeostasis [31]. Typically, under stimuli, the astrocytes react by 
proliferation or the hypertrophy of cytoplasmic processes and increased expression of 
the intermediate filament protein GFAP from astrocyte cytoskeleton. They are also able 
to increase or decrease the expression of the gap-junction (GJ) protein connexin-43 
(Cx43) depending on the stimulus, thus regulating the exchange of information between 
cells. Changes in the expression of Cx43 and the exchange of information among 
astrocytes are relevant to many brain lesions and pathologies [32], as they can result in 
the dissemination of the pathological state and/or the accumulation of toxicants in the 
absence of functional GJ channels [33].  
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A recent study reported that the lack of Cx43 expression or the blockade of 
Cx43 channels results in increased reactive oxygen species (ROS)-induced astrocytic 
death [34], one of the several mechanisms leading to nanotoxicity [35].  
 
3.4 PEGylation of rGO increased ROS generation  
To further widen our understanding of the mechanisms triggering toxicity we 
investigated if rGO-PEG treatment affects ROS generation (in vitro) and the antioxidant 
enzymatic system (in vivo) in comparison with the effect of non-PEGylated rGO.  
Measurement of ROS formation was performed using an oxidant-sensitive 
fluorogenic probe CM-H2DCFDA (5-(6)-chloromethyl-2′,7′-dichlorodihydrofluorescein 
diacetate, acetyl ester). An increase in CM-H2DCFDA fluorescence reflects an increase 
in ROS levels [36]. 
Following a 24 h exposure of astrocytes to nanomaterials, intracellular ROS 
levels significantly increased in both PEGylated and non-PEGylated rGO-treated cells 
(Figure 6A). The highest concentration of rGO-PEG induced a 270% increase in the 
intracellular levels of ROS (p<0.001), while rGO induced a 33% increase (p<0.001), in 
comparison with their respective vehicle controls.  
The non-PEGylated rGO did not induce ROS production in RBECs, but as with 
the astrocytes response, the highest concentration (100 µg/ml) of rGO-PEG enhanced 
the generation of ROS (p<0.001) in RBECs, in comparison with all other groups (Figure 
6B). 
This data supports our hypothesis that oxidative stress is a major factor in the 
toxicity of rGO-PEG. The induction of ROS generation seems to be a general cellular 
response to rGO-PEG. Reshma et al. [37] described the production of ROS in A549 
cells after treatment with PEGylated rGO and non-PEGylated rGO. Their results reveal 
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that PEGylated rGO were able to induce prominent ROS production at all time-points 
(0.5, 2, 4, 5 and 24 h) and at concentrations ranging from 5 to 100 µg/ml. The authors 
found that rGO failed to generate ROS at up to 4 h as the concentration of the particle 
increased from 5 to 100 µg/ml. However, ROS generation increased after 6 h of 
exposure to 50 µg/ml and after 6 and 24 h of exposure to 100 µg/ml. The findings show 
that the formation of ROS depends of variables such as time of exposure and the 
concentration of the nanoparticle, which may suggest that antioxidant activity is likely 
to depend on the same variables. 
The detoxification of excess ROS is mediated by an efficient antioxidant system 
comprising non-enzymatic molecules and antioxidant enzymes [38], the most efficient 
of which are enzymatic antioxidants glutathione peroxidase, catalase and superoxide 
dismutase (SOD) [39]. 
We initiated our in vivo analysis by evaluating the protein expression of catalase 
and SOD-1 in the hippocampus. As shown in Figure 7, the expression of catalase was 
27% higher at 3 h (p<0.01) and 18% higher at 7 days (p<0.05) post-rGO-PEG 
administration, in comparison with control levels. Interestingly, only a 12% increase 
was detected in SOD-1 expression by day 7 (Figure 7B).  
To determine whether the protein levels of catalase and SOD-1 in hippocampus 
paralleled the activity level of the enzymes, we measured total SODs and catalase 
activities from serum samples. Over time, increases in the antioxidant enzymes and in 
lipid peroxidation measured by thiobarbituric acid reactive substances (TBARS) were 
observed (Table 3). 
SOD catalyzes the conversion of superoxide anions to oxygen and hydrogen 
peroxide. Thus, CAT converts hydrogen peroxide to water and oxygen and completes 
the detoxification initiated by SOD [39]. It has been found that cells can tolerate 
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moderate oxidative stress by up-regulating their reductive defense systems and restoring 
the oxidant/antioxidant balance [40]. Taken together, these results indicate that the 
increase in catalase and SOD activity/expression could be due to oxidative stress 
generation and may suggest a possible adaptive mechanism against insults caused by 
rGO-PEG administration. 
 
Table 3. Serum levels of SOD, catalase and TBARS after rGO-PEG treatment. 
 Unit Control rGO-PEG  
15 min 
rGO-PEG  
1 h 
rGO-PEG  
3 h 
rGO-PEG  
7 d 
CAT nmol/min/ml 64 ± 14.6 71 ± 12.8 88 ± 19.8 89 ± 9.4 123 ± 18.3* 
SOD U/ml 35 ± 2.2 56 ± 7.8 43 ± 0.5* 49 ±2.4** 49 ± 3.9* 
TBARS nmol/ml 3.0 ± 0.8 2.9 ± 0.7 3.4 ± 0.5 3.5 ± 0.2 4.4 ± 0.7 
 SOD: superoxide dismutase; CAT: catalase; TBARS: Thiobarbituric acid reactive substances. Values are 
mean +/-SEM of 3-4 animals in each group. *p<0.05 and **p<0.01 compared to control (Student's t test). 
 
4. CONCLUSIONS 
The PEGylation of nanomaterials and therapeutics is currently considered to be 
one of the most promising approaches to reducing toxicity and obtaining favorable 
pharmacokinetic results. However, deleterious effects and death have been observed in 
different cell types treated with PEGylated nanoparticles, mostly through the induction 
of oxidative stress, which corroborated the results of the present experimental design. 
 Herein, the combined in vitro and in vivo toxicity profiles of PEGylated rGO 
have been investigated and reported for the first time. The data of the present study 
suggest the dose- and time-dependent toxicity of PEGylated rGO for key components of 
the blood-brain barrier, such as astrocytes and endothelial cells. In terms of toxicity 
mechanisms, the formation of intracellular ROS and the increase in the enzymatic 
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antioxidant system induced by PEGylated-rGO suggest oxidative stress-mediated 
damage. 
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Figure legends 
 
Figure 1. rGO-PEG characterization. (A) Fourier-transform infrared spectroscopy in 
the attenuated total reflectance mode (FTIR-ATR); (B) TGA curves of rGO-PEG; 13C 
NMR spectra of (C) rGO and (D) rGO-PEG; (E) Representative FE-SEM and (D) 
HRTEM images showing part of rGO-PEG. A.u = Arbitrary units. 
 
Figure 2. Effect of rGO and rGO-PEG treatment on cultures of rat astrocytes. 
Astrocytes were incubated with different concentrations (10 µg/ml and 100 µg/ml) of 
(A) rGO and rGO-PEG during 24 h. Culture medium was used as negative control. The 
rGO vehicle (sterile distilled water) and rGO-PEG vehicle (PEG) were used as controls. 
The viability of the cells was measured using EZ4U assay 24 h after rGO or rGO-PEG 
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treatment. The percentage is given in relation to control medium and the columns are 
the mean ± SEM (n=4). (B) Analysis of cell viability using xCELLigence system. 
The curves represent the average of four individual well ± SEM of a representative 
experiment. (C-H) Representative immunofluorescence images for glial fibrillary acidic 
protein (GFAP) (red) and Aquaporin-4 (green) after (C) sterile distilled water, (F) PEG,  
(D, G) rGO 100 µg/ml, and (E, H) rGO-PEG 100 µg/ml treatment. Nuclei were stained 
with Hoechst (blue). ***p<0.001 vs. all other groups; φφφp<0.001 vs. all other groups 
(One-way ANOVA plus Tukey post-comparison test). Bar: 100 µm for all panels. 
 
Figure 3. Effects of rGO and rGO-PEG treatment on RBECs. Analyses of cell 
viability using (A) EZ4U assay and (B) xCELLigence system. Culture medium was 
used as negative control. The rGO vehicle (sterile distilled water) and rGO-PEG vehicle 
(PEG) were used as blank controls. The viability of the cells was measured using EZ4U 
assay 3 h 30 min after rGO or rGO-PEG treatment. The percentage is given in relation 
to control medium and the columns are the mean ± SEM (n=4). (B) Analysis of cell 
viability using xCELLigence system. The curves represent the average of four 
individual well ± SEM of a representative experiment. (C-F) Double immunostaining 
for claudin-5 (red) and occludin (green) performed 5 h after treatment with 100 µg/ml 
of (C) sterile distilled water, (D) rGO, (E) PEG and (F) rGO-PEG. Nuclei were stained 
with Hoechst (blue). Asterisks show holes formed between endothelial cells. Arrows 
indicate fragmentation and loss of junctional immunostaining. #p<0.05 vs. control PEG 
100 µg/ml; ###p<0.001 vs. all other groups; *p<0.05 vs. control PEG 10 
µg/ml;***p<0.001 vs. all other groups; φφφp<0.001 vs. all other groups (One-way 
ANOVA plus Tukey post-comparison test). Bar: 100 µm for all panels. 
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Figure 4. Expression of proteins associated with BBB in the hippocampus as 
assessed by western blotting. The panels show the expression of (A) occludin, (B) β-
catenin and (C) laminin at different intervals after rGO-PEG administration (7 mg/kg, 
i.v.). Immunoreactive bands were quantified densitometrically and normalized to an 
internal standard (β-actin). The results were shown as percentage of control (100%), and 
represent mean ± SEM (n = 5 rats/interval). *p<0.05, **p<0.01 and ***p<0.001 
compared to the control (Student's t-test). 
 
Figure 5. Effects of rGO-PEG treatment on astrocytic markers in vivo. Expression 
of (A) GFAP and (B) Cx43 at different intervals after rGO and rGO-PEG (7 mg/kg, i.v.) 
administration. Immunoreactive bands were quantified densitometrically and 
normalized to an internal standard (β-actin). The results were shown as percentage of 
control (100%), and represent mean ± SEM (n = 5 rats/interval). Representative images 
of GFAP immunostaining (brown color) in CA1 hippocampal region. (C) Control PEG, 
(D) 3 h and (E) 7 days after rGO-PEG treatment. A = #p<0.05 vs. control H2O, control 
PEG, rGO-PEG 1h; *p<0.05 vs. rGO 3 h, 7d; **p<0.01 vs. rGO 15 min, 1 h, rGO-PEG 
15 min; ***p<0.001 vs. control H2O, control PEG, rGO-PEG 1 h. B = *p<0.05 vs. rGO 
15 min, 3 h, 7 d, rGO-PEG 1 h; ***p<0.001 vs. control H2O, rGO  1 h, control PEG 
(One-way ANOVA plus Tukey post-comparison test). Bar: 50 µm. 
 
Figure 6. ROS levels in astrocytes and RBECs incubated with rGO and rGO-PEG. 
Intracellular ROS levels were detected with CM-H2-DCFDA in (A) astrocytes and (B) 
RBECs after 24 h and 3 h and 30 min, respectively. The bars show the quantitative 
analysis of fluorescent intensity from four experiments. Data represent the mean ± 
SEM. A = φp<0.05 vs. control PEG 10 µg/ml; φφp<0.01 vs. control PEG 100 µg/ml; 
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###p<0.001 vs. control PEG 10 µg/ml, rGO-PEG 10 µg/ml, control PEG 100 µg/ml; 
***p<0.001 vs. all other groups. B = φφp<0.01 vs. control H2O 10 µg/ml, 100 µg/ml, 
#p<0.05 vs. control H2O 10 µg/ml, 100 µg/ml; ***p<0.001 vs. all other groups (One-
way ANOVA plus Tukey post-comparison test). 
 
Figure 7. Effects of rGO-PEG administration in antioxidant enzymes. (A) 
Densitometric analysis of (A) catalase and (B) SOD-1 performed after normalization 
with β-action. The results were expressed as percentage of control (100%) and columns 
represent the mean ± SEM (n=5 rats/interval). *p<0.05, **p<0.01 and ***p<0.001 
compared to the control (Student's t test). 
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